Galen’s business development activities continue to drive our growth in both existing and new markets, through licensing, acquisition and partnership. Currently, we collaborate successfully with a number of international pharmaceutical companies and continue to search for opportunities to launch new products within our core markets and to partner the Galen portfolio around the world.
Galen has an established commercial infrastructure in both the UK and US, with key business strengths, which enable us to be recognised as a partner of choice. In these markets, we are seeking to expand our product range through acquisition of additional in-market products or in-licensing of near market opportunities.
Following the acquisition of Synera® (lidocaine and tetracaine) Topical Patch, Galen’s search for new US opportunities is focused on specialty branded products, which could be incorporated into our sales and marketing activities within paediatric hospitals.
In the UK, Galen aims to identify further products, which would build our “Trustsaver®” offering, where we aim to work in partnership with healthcare professionals, patients and payors, by offering branded products with a cost saving to the NHS, across a broad range of therapy areas.
These products will complement our current product range and development projects, being progressed with our sister company, the Almac Group, to build a pipeline for commercialisation around the world through a network of strategic business partners.
If you would like to discuss how Galen’s expertise could add value to your product in the US and UK, or learn more about partnering with Galen, please contact our business development team.